Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Keymed Biosciences, Inc. (2162) Stock Price & Analysis

1 Followers

2162 Stock Chart & Stats

HK$69.85-HK$1.15(-1.62%)
At close: 4:00 PM GMT+8
HK$70HK$80Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 68.50 - HKD 71.80
52-Week Range
HKD 44.66 - HKD 89.75
Previous Close
HKD 71.00
Volume
N/A
Average Volume (3M)
2.54M
Market Cap
HKD 19.93B
Enterprise Value
HKD 17.31B
Total Cash (Recent Filing)
HKD 3.24B
Total Debt (Recent Filing)
HKD 696.57M
Price to Earnings (P/E)
21.4
Beta
0.86
Next Earnings
Mar 30, 2027 (Est.)
EPS Estimate
-1.53
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Gross Margin

A gross margin near 74% indicates that Keymed retains substantial value after direct product costs. If commercial scale improves, this margin structure could provide operating leverage and support future reinvestment in antibody development, commercialization, and licensing activities.

Scaled Revenue Base

Revenue has expanded meaningfully over the period shown, demonstrating that Keymed has built a substantially larger commercial and development-related revenue base than in 2022. This scale can improve market reach and create a stronger platform for future product or partnership growth.

Positive Equity And Moderate Leverage

A sizable positive equity base and moderate leverage provide a comparatively stronger financial foundation for a biotechnology company funding long-cycle research and commercialization. This balance-sheet position offers more flexibility to continue investing than a highly levered structure would allow.

Bears Say

Persistent Operating Losses

Deep operating and net losses show that Keymed has not yet converted its revenue base into sustainable profitability. Continued losses can constrain internal funding, weaken shareholder returns, and make the company more dependent on financing or successful pipeline progress to reach breakeven.

Sustained Cash Burn

Consistently negative operating and free cash flow indicates that the business is consuming substantial cash while developing and operating its programs. Persistent burn reduces financial flexibility over the medium term and increases the importance of maintaining financing capacity or improving cash generation.

2025 Revenue Contraction

The reversal from earlier revenue growth to an approximately 20% decline in 2025 raises concerns about the durability and consistency of Keymed's commercial momentum. A shrinking top line makes it harder to absorb the existing cost base and delays the operating leverage needed for profitability.

Keymed Biosciences, Inc. News

2162 FAQ

What was Keymed Biosciences, Inc.’s price range in the past 12 months?
Keymed Biosciences, Inc. lowest stock price was HK$44.66 and its highest was HK$89.75 in the past 12 months.
What is Keymed Biosciences, Inc.’s market cap?
Keymed Biosciences, Inc.’s market cap is HK$19.93B.
When is Keymed Biosciences, Inc.’s upcoming earnings report date?
Keymed Biosciences, Inc.’s next earnings report is estimated for Mar 30, 2027 (not yet confirmed), which is in 136 days.
How were Keymed Biosciences, Inc.’s earnings last quarter?
Keymed Biosciences, Inc. released its earnings results on Aug 20, 2026. The company reported HK$5.027 earnings per share for the quarter, missing the consensus estimate of HK$5.391 by -HK$0.363.
Is Keymed Biosciences, Inc. overvalued?
According to Wall Street analysts Keymed Biosciences, Inc.’s price is currently Undervalued.
Does Keymed Biosciences, Inc. pay dividends?
Keymed Biosciences, Inc. does not currently pay dividends.
What is Keymed Biosciences, Inc.’s EPS estimate?
Keymed Biosciences, Inc.’s EPS estimate is -1.53.
How many shares outstanding does Keymed Biosciences, Inc. have?
Keymed Biosciences, Inc. has 298,735,570 shares outstanding.
What happened to Keymed Biosciences, Inc.’s price movement after its last earnings report?
Keymed Biosciences, Inc. reported an EPS of HK$5.027 in its last earnings report, missing expectations of HK$5.391. Following the earnings report the stock price went up 0.909%.
Which hedge fund is a major shareholder of Keymed Biosciences, Inc.?
Currently, no hedge funds are holding shares in HK:2162
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology